Cited 1 times in
The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정준원 | - |
dc.date.accessioned | 2022-12-22T01:41:12Z | - |
dc.date.available | 2022-12-22T01:41:12Z | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 0145-2126 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191300 | - |
dc.description.abstract | Genetic differences may be associated with the response to tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia (CML). In this study, we identified genetic alterations between rapid and slow responders (BCR/ABL1 International Scale at 6 months: ≤0.1 % vs. > 0.1 %) of TKI treatment in chronic phase CML patients. Our analyses involved single nucleotide polymorphism (SNP), a Genome Wide Association Study and a Network-wide Association Study (NetWAS). Seventy-two patients from 16 institutions were enrolled and treated with a TKI, nilotinib. Gene Set Analysis identified genetic alterations in pathways related to the differentiation, proliferation, and activity of various innate immune cells. The NetWAS analysis found that genes associated with natural killer (NK) cells (PTPRCAP, BLNK, HCK, ARHGEF11, GPR183, TRPV2, SHKBP1, CD2) showed significant differences between rapid and slow responders of nilotinib. However, we found no significantly different genetic alterations according to the response in the SNP analysis. In conclusion, we found that rapidity of response to TKI was associated with pathway-associated genetic alterations in immune cells, particularly with respect to NK cell activity. These results suggested that the innate immune system at initial diagnosis had an important role in treatment response in patients with CML. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Pergamon Press | - |
dc.relation.isPartOf | LEUKEMIA RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Fusion Proteins, bcr-abl / genetics | - |
dc.subject.MESH | Genome-Wide Association Study* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Killer Cells, Natural / metabolism | - |
dc.subject.MESH | Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / diagnosis | - |
dc.subject.MESH | Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy | - |
dc.subject.MESH | Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Protein Kinase Inhibitors / pharmacology | - |
dc.subject.MESH | Protein Kinase Inhibitors / therapeutic use | - |
dc.title | The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyunkyung Park | - |
dc.contributor.googleauthor | Sungbong Kang | - |
dc.contributor.googleauthor | Inho Kim | - |
dc.contributor.googleauthor | Sangsoo Kim | - |
dc.contributor.googleauthor | Hyeong-Joon Kim | - |
dc.contributor.googleauthor | Dong-Yeop Shin | - |
dc.contributor.googleauthor | Dae-Young Kim | - |
dc.contributor.googleauthor | Kyoo-Hyung Lee | - |
dc.contributor.googleauthor | Jae-Sook Ahn | - |
dc.contributor.googleauthor | Sang-Kyun Sohn | - |
dc.contributor.googleauthor | Jeong-Ok Lee | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Kyoung Ha Kim | - |
dc.contributor.googleauthor | Hoon-Gu Kim | - |
dc.contributor.googleauthor | Hawk Kim | - |
dc.contributor.googleauthor | Yoo Jin Lee | - |
dc.contributor.googleauthor | Seung-Hyun Nam | - |
dc.contributor.googleauthor | Young Rok Do | - |
dc.contributor.googleauthor | Sang-Gon Park | - |
dc.contributor.googleauthor | Seong Kyu Park | - |
dc.contributor.googleauthor | Hun Ho Song | - |
dc.contributor.googleauthor | Chul Won Jung | - |
dc.contributor.googleauthor | Seonyang Park | - |
dc.identifier.doi | 10.1016/j.leukres.2022.106791 | - |
dc.contributor.localId | A03729 | - |
dc.relation.journalcode | J02166 | - |
dc.identifier.eissn | 1873-5835 | - |
dc.identifier.pmid | 35101736 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0145212622000170?via%3Dihub | - |
dc.subject.keyword | Chronic myeloid leukemia | - |
dc.subject.keyword | Genetic analysis | - |
dc.subject.keyword | Molecular response | - |
dc.subject.keyword | Natural killer cell | - |
dc.subject.keyword | Tyrosine kinase | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.affiliatedAuthor | 정준원 | - |
dc.citation.volume | 114 | - |
dc.citation.startPage | 106791 | - |
dc.identifier.bibliographicCitation | LEUKEMIA RESEARCH, Vol.114 : 106791, 2022-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.